New LaunchJul 9, 2026, 08:06 AM
Scienture to Launch REZENOPY™ Naloxone Nasal Spray in August
AI Summary
Scienture Holdings, Inc. announced the completion of manufacturing for REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers later this month. The company expects the highest-dose FDA-approved naloxone nasal spray to be commercially available for purchase in August. This launch targets the significant U.S. naloxone market, which totals approximately $144 million in annual sales and 9.8 million units, and follows expanded payer access covering over 100 million lives.
Key Highlights
- REZENOPY™ commercial availability expected in August 2026
- Shipments of REZENOPY™ to U.S. wholesalers begin late July 2026
- REZENOPY™ is the highest-dose FDA-approved naloxone nasal spray (10 mg)
- U.S. naloxone market totals ~$144 million in annual sales
- U.S. naloxone market represents ~9.8 million units annually
- Payer access expanded to over 100 million covered lives for REZENOPY™
- REZENOPY™ received FDA approval on April 19, 2024
Price Impact
More from SCNX